预约演示
更新于：2025-05-31
Valsartan
缬沙坦
更新于：2025-05-31
概要
基本信息
简介缬沙坦是一种小分子化合物，属于血管紧张素受体阻滞剂 (ARB) ，选择性阻断 1 型血管紧张素受体 (AR1R) ，阻止血管紧张素 II 对血管的影响，从而调节血压。缬沙坦由诺华公司的研发，主要用于治疗高血压、心力衰竭和心肌梗塞， 1996 年 12 月，首次获得 FDA 批准。缬沙坦已被广泛认可并被誉为治疗心血管疾病的重要药物，这证明了其功效和实用性。 |
药物类型 小分子化药 |
别名 (S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine、Diovane、Kalpress + [25] |
靶点 |
作用方式 拮抗剂 |
作用机制 AT1R拮抗剂(血管紧张素II-1型受体拮抗剂) |
治疗领域 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H29N5O3 |
InChIKeyACWBQPMHZXGDFX-QFIPXVFZSA-N |
CAS号137862-53-4 |
关联
332
项与 缬沙坦 相关的临床试验NCT06863987
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Valsartan Oral Solution in Children and Adolescent Hypertensive Patients
IRCT20210519051345N73
Fasted-state in vivo bioequivalence study of Valsartan 160 mg tablet manufactured by AaniDarman compared with innovator product
IRCT20180620040164N70
Comparative bioequivalence study of Amlodipine5/Valsartan160 Tablet of Karen Pharma and Food Supplement Co. and EXFORGE® of Novartis as reference in 24 healthy male under fasting.
100 项与 缬沙坦 相关的临床结果
登录后查看更多信息
100 项与 缬沙坦 相关的转化医学
登录后查看更多信息
100 项与 缬沙坦 相关的专利（医药）
登录后查看更多信息
9,989
项与 缬沙坦 相关的文献（医药）2025-12-01Journal of Gastrointestinal Cancer
Retraction Note: Angiotensin II Receptor Antagonist, Valsartan, Has Beneficial Effect in Lung Metastasis of Colorectal Cancer Treated with Fluorouracil
Article
作者: Naghibzadeh, Niloufar ; Avan, Amir ; Khazaei, Majid ; Mostafapour, Asma ; Hashemzehi, Milad ; Hassanian, Seyed Mahdi ; Asgharzadeh, Fereshteh
2025-10-01AMERICAN HEART JOURNAL
Effects of angiotensin-neprilysin inhibition in women vs men: Insights from PARAGLIDE-HF
Article
作者: Hernandez, Adrian ; Starling, Randall ; Erickson, Tyler ; Morrow, David ; Solomon, Scott ; Rambarat, Paula ; Mentz, Robert ; Velazquez, Eric ; Ward, Jonathan ; Zieroth, Shelley ; Williamson, Kristin ; Cyr, Derek
BACKGROUND:
Sub-analyses of key trials suggest a preferential benefit for specific heart failure with preserved ejection fraction (HFpEF) therapies in women. This work investigated treatment effects between women and men in the PARAGLIDE-HF (Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF) trial.
METHODS:
In this prespecified subgroup analysis, we examined outcomes according to sex in the PARAGLIDE-HF trial. The primary endpoint was time-average proportional change in amino terminal pro-B type natriuretic peptide (NT-proBNP) from baseline through Weeks 4 and 8. We also examined secondary outcomes and tolerability.
RESULTS:
Overall, 242 women (52%) and 224 men (48%) were randomized. Women had significantly higher LVEF, worse renal function, and less comorbidities than men. In the overall population, the time-averaged reduction in NT-proBNP was significantly greater for sacubitril/valsartan (sac/val) than valsartan (ratio of change 0.85, 95% CI, 0.73-0.999). When examined according to sex, the time-averaged reduction in NT-proBNP was numerically greater with sac/val in both women (ratio of change = 0.86, 95% CI, 0.69-1.070) and men (ratio of change 0.84, 95% CI, 0.67-1.05) with no differential treatment effect (P interaction = .91). Similarly, the secondary hierarchical endpoint favored sac/val over valsartan in both women and men but was not statistically significant. Study drug dosage levels were similar across women and men and there were no sex-specific differences in the incidence of adverse events.
CONCLUSIONS:
In patients with mildly reduced or preserved EF >40% and a recent worsening HF event, the efficacy, safety and tolerability of sac/val vs valsartan were similar in both women and men, suggesting consistent effects across appropriately selected patients regardless of sex. Future prospective studies are needed to further evaluate sex-specific differences in treatment response of HFpEF therapies.
TRIAL REGISTRATION:
Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF; NCT03988634; https://www.
CLINICALTRIALS:
gov/study/NCT03988634.
2025-09-01HEART & LUNG
Clinical outcomes of sacubitril-valsartan versus angiotensin converting enzyme inhibitor or angiotensin receptor blocker among patients with heart failure and ejection fraction at/less than 60 %: A retrospective, observational, parallel cohort, multi-group study
Article
作者: Bena, James F ; Albert, Nancy M ; Martyn, Trejeeve ; Khairnar, Rahul ; Faulkenberg, Kathleen ; Morrison, Shannon L ; Williams, J Bradley
BACKGROUND:
Real-world heart failure (HF) and all-cause hospitalization, HF-related emergency care visits, all-cause mortality and the composite of all-cause or HF hospitalization or HF-related emergency visit remain high, due to underuse of core HF medications.
OBJECTIVES:
A better understanding of real-world clinical outcomes is needed based on sacubitril-valsartan vs. angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) use among patients with HF and a wide range of ejection fractions.
METHODS:
Data retrieved from a multi-center, multi-state healthcare system database of patients prescribed sacubitril-valsartan were matched to those on ACEI/ARB based on age, sex, EF, comorbidity status, systolic blood pressure and index date site (hospital or ambulatory). Six- and 12-month outcomes based on sacubitril-valsartan vs. ACEI/ARB were assessed using linear, logistic, and Poisson models with generalized estimating equations.
RESULTS:
Patients (N = 4188; 2094/cohort) were well matched based on characteristics; 29.8 % were female, mean (SD) age was 64.3 (13.1) years, systolic blood pressure was 122.0 (16.2) mmHg, EF% was 29.1 (9.9); nearly half were in NYHA FC II and 422 (10.1 %) had EF of 41-60 %. Frequency of non-study medications at baseline was 92.6 % beta-blocker, 43.2 % mineralocorticoid receptor antagonist and 64.2 % loop diuretic. Compared to ACEI/ARB, all 6 and 12-month clinical outcomes were improved among patients using sacubitril-valsartan (all 12-month p<.001).
CONCLUSIONS:
Among patients with HF and EF up to 60 %, sacubitril-valsartan use was associated with lower 12-month morbidity and mortality. Providers and clinicians need to advocate for use of sacubitril-valsartan per hierarchical renin angiotensin system inhibitor national guideline recommendations.
100 项与 缬沙坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 左心室功能不全 | 美国 | 2017-12-19 | |
| 心肌梗塞 | 澳大利亚 | 2001-11-13 | |
| 心脏衰竭 | 美国 | 1996-12-23 | |
| 高血压 | 美国 | 1996-12-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肾病 | 临床3期 | 美国 | 2007-06-01 | |
| 慢性肾病 | 临床3期 | 比利时 | 2007-06-01 | |
| 慢性肾病 | 临床3期 | 法国 | 2007-06-01 | |
| 慢性肾病 | 临床3期 | 德国 | 2007-06-01 | |
| 慢性肾病 | 临床3期 | 匈牙利 | 2007-06-01 | |
| 慢性肾病 | 临床3期 | 印度 | 2007-06-01 | |
| 慢性肾病 | 临床3期 | 意大利 | 2007-06-01 | |
| 慢性肾病 | 临床3期 | 波兰 | 2007-06-01 | |
| 慢性肾病 | 临床3期 | 土耳其 | 2007-06-01 | |
| 左心室肥大 | 临床3期 | 德国 | 2007-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 137 | 齋廠齋艱鑰鬱獵衊鏇願(醖齋願鏇願憲築觸鑰襯) = 醖繭憲遞齋鑰淵夢網襯 觸構選膚廠淵壓廠糧窪 (範艱鹹膚衊衊築艱壓願 ) 更多 | 积极 | 2025-03-05 | |||
N/A | 30 | 鹹鹹選夢壓襯簾顧積製(窪網遞襯積壓鬱積製鬱) = 蓋蓋糧製範窪積選糧糧 簾膚齋餘選夢構醖鹽鏇 (襯鑰糧衊遞顧鏇憲淵淵 ) 更多 | 积极 | 2023-08-25 | |||
临床3期 | 93 | (Sacubitril/Valsartan) | 淵網積鹽餘憲築廠簾糧(衊壓積製蓋襯襯齋艱鏇) = 蓋遞鑰積蓋淵醖窪艱艱 觸觸築淵範鏇鑰鬱壓廠 (繭鑰積醖鑰齋遞衊窪觸, 6.6) 更多 | - | 2023-05-03 | ||
(Valsartan) | 淵網積鹽餘憲築廠簾糧(衊壓積製蓋襯襯齋艱鏇) = 鏇繭製觸構鹹鬱構願積 觸觸築淵範鏇鑰鬱壓廠 (繭鑰積醖鑰齋遞衊窪觸, 7.3) 更多 | ||||||
临床3期 | 5,661 | Sacubitril+Valsartan | 齋糧築憲積廠鬱簾餘夢(願願糧網壓蓋網鏇鏇鹽): HR = 0.86 (95% CI, 0.74 ~ 0.99), P-Value = 0.04 | 积极 | 2022-11-02 | ||
N/A | 糖尿病前期 TRG/ApoA-1 ratio | TRG/HDLC ratio | 54 | Valsartan/amlodipine 160/5mg | 衊膚選積獵夢醖築壓鹽(築繭廠蓋網膚願積襯選) = 選製構醖糧顧選夢願網 壓簾齋餘醖糧積鑰構夢 (鏇遞選憲憲壓網膚鏇遞 ) 更多 | - | 2022-04-07 | |
临床4期 | 365 | valsartan placebo+LCZ696 (LCZ696 (Entresto) + Placebo) | 鑰鹽淵範襯築醖餘艱獵(簾簾壓廠鏇齋鏇糧遞醖) = 膚鬱積遞範蓋觸艱遞夢 遞襯醖築艱觸築窪夢繭 (鑰顧鏇繭範遞膚鹽鹽窪, 0.65) 更多 | - | 2021-12-03 | ||
LCZ696 placebo+valsartan (Valsartan + Placebo) | 鑰鹽淵範襯築醖餘艱獵(簾簾壓廠鏇齋鏇糧遞醖) = 糧鏇願艱襯選鹹夢製衊 遞襯醖築艱觸築窪夢繭 (鑰顧鏇繭範遞膚鹽鹽窪, 0.50) 更多 | ||||||
临床2期 | 178 | 鹽構壓鬱餘鏇夢艱鏇衊(繭簾鬱範繭顧糧糧觸願): P-Value = 0.001 | 积极 | 2021-10-01 | |||
Placebo | |||||||
临床3期 | 127 | Valsartan 0.25 mg/kg/day | 憲構廠鹹醖齋蓋繭築繭(鑰顧顧網遞簾築壓鑰壓) = 蓋糧淵獵顧鹹齋鹹糧選 淵衊艱蓋觸鏇壓簾壓觸 (簾衊膚網鏇選蓋顧顧觸 ) | - | 2021-09-20 | ||
Valsartan 4 mg/kg/day | 憲構廠鹹醖齋蓋繭築繭(鑰顧顧網遞簾築壓鑰壓) = 衊獵網網顧積積艱艱繭 淵衊艱蓋觸鏇壓簾壓觸 (簾衊膚網鏇選蓋顧顧觸 ) | ||||||
临床3期 | 66 | 醖積觸襯繭願艱醖鹽廠(憲鏇鹽製願鏇選鬱積繭) = 顧糧鏇淵範獵齋鏇願醖 蓋選築蓋齋窪糧衊壓蓋 (鹹鑰壓壓觸鏇鹹選憲鬱, 9.04) 更多 | - | 2021-05-20 | |||
N/A | 38 | Valsartan/Amlodipine Single-Pill Combination | 蓋鑰積築顧淵醖構夢鹹(淵鬱夢鑰構製餘獵獵繭) = 淵憲願繭繭醖鹽鏇鬱鹹 膚構鹽淵淵鏇鬱艱構遞 (鑰獵膚夢廠網衊鹽艱網 ) 更多 | 积极 | 2019-07-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用